The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

USA-based Elevation Oncology, an innovative oncology company focused on the discovery and development of selective cancer ...

Investing.com -- Lonza’s shares rose over 6% on Thursday following the company’s announcement of plans to divest its Capsules ...

Elevation Oncology has tapped Lonza’s Synaffix to support the expansion of its pipeline, agreeing to pay up to $368 million ...

With a new CEO at the helm, Swiss CDMO Lonza is looking to revivify its business by doubling down on contract manufacturing ...

Recent developments in the health sector include a dosing pause in Keros Therapeutics' drug trial, Corcept Therapeutics' ALS ...

By Isabel Demetz (Reuters) -Swiss contract drugmaker Lonza plans to simplify its structure and exit its capsules and health ...

Lonza forecasts 2025 CER sales growth of nearly 20%, supported by organic growth and acquisitions, with CORE EBITDA margins nearing 30%. The streamlined organizational model, operational by Q2 2025, ...

Synaffix B.V., a Lonza company (SIX: LONN) focused on commercializing its clinical-stage platform technology for the development ...

Licensing agreement gives Elevation Oncology access to Synaffix's ADC technology for one program in combination with SYNstatin EElevation Oncology nominates a novel HER3 ADC candidate EO-1022 ...

The life-sciences company will focus on its core business, including drug development, with restructuring and a divestment ...

Lonza Group AG / Key word (s): Strategic Company Decision Lonza Investor Update 2024 Outlines Strategy, New Organizational Structure and Guidance 12-Dec-2024 / 06:25 CET/CEST Release of an ad hoc ...